- Herpes simplex virus-induced cardiomyopathy successfully treated with acyclovir2010 | First Faculty of Medicine
- Neurotoxic side effects of acyclovir: two case reports2021 | First Faculty of Medicine, Faculty of Physical Education and Sport, Second Faculty of Medicine
- Influence of plasticizer type and concentration on acyclovir release from branched oligoester matrices2007 | Publication without faculty affiliation
- Darier disease complicated by severe Kaposi varicelliform eruption resistant to acyclovir2020 | Third Faculty of Medicine
- Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity2012 | Second Faculty of Medicine
- Rheological evaluation of the adhesive oligoester matrices with acyclovirPublication without faculty affiliation
- Acyclovir - a drug with variable kineticsPublication without faculty affiliation
- Determination of acyclovir by RP-HPLC with fluorescence detection. Application to a pharmacokinetic studyPublication without faculty affiliation
- Influence of plasticizer type and concentration on acyclovir release from branched oligoester matrices2007 | Faculty of Pharmacy in Hradec Králové
- Herpes simplex virus resistant to acyclovir: A single-centre experience from the Czech Republic2019 | Faculty of Medicine in Hradec Králové
- High Doses of Acyclovir: A New Concept in the Treatment of Neonatal Herpes Simplex Virus Infection2004 | First Faculty of Medicine
- High Doses of Acyclovir: A New Concept in the Treatment of Neonatal Herpes Simplex Virus Infection2004 | Faculty of Physical Education and Sport
- Recurrent genital herpes2008 | First Faculty of Medicine
- Mucoadhesive plasticized system of branched poly(lactic-co-glycolic acid) with aciclovir2016 | Faculty of Pharmacy in Hradec Králové
- Sore throat in children2005 | First Faculty of Medicine
- Antivirotics against herpetic viruses2013 | First Faculty of Medicine
- Mollaret's meningitis2003 | First Faculty of Medicine
- Current management of herpes zoster - The European view2005 | Second Faculty of Medicine
- Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study2019 | First Faculty of Medicine